Sanofi $SNY Stock Holdings Lowered by Aberdeen Group plc

Key Points

• Aberdeen Group plc has reduced its stake in Sanofi by 37.6%, selling over 118,000 shares during the first quarter, leaving them with 196,048 shares valued at approximately $10.87 million.
• Other institutional investors have increased their holdings, with Mirae Asset Global Investments growing its position by 124%, and several others like Axxcess Wealth Management and Ballentine Partners also significantly increasing their shares.
• Sanofi reported a quarterly earnings miss with $0.90 earnings per share, below the estimated $0.96, while its revenue for the quarter was $11.34 billion, surpassing projections.

Aberdeen Group plc lowered its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 37.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 196,048 shares of the company's stock after selling 118,132 shares during the period. Aberdeen Group plc's holdings in Sanofi were worth $10,873,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Sanofi by 124.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock worth $1,344,000 after acquiring an additional 13,358 shares during the last quarter. Axxcess Wealth Management LLC grew its position in Sanofi by 130.5% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock valued at $568,000 after buying an additional 5,794 shares in the last quarter. Ballentine Partners LLC grew its position in Sanofi by 68.7% in the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock valued at $1,445,000 after buying an additional 10,617 shares in the last quarter. Sowell Financial Services LLC bought a new position in Sanofi in the 1st quarter valued at about $328,000. Finally, Farther Finance Advisors LLC grew its position in Sanofi by 66.2% in the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock valued at $338,000 after buying an additional 2,476 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

NASDAQ:SNY opened at $50.19 on Wednesday. Sanofi has a twelve month low of $44.73 and a twelve month high of $60.12. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average of $48.57 and a 200-day moving average of $51.77. The firm has a market cap of $123.24 billion, a price-to-earnings ratio of 12.06, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter last year, the business posted $1.73 EPS. The business's revenue for the quarter was down 7.0% on a year-over-year basis. Analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SNY. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research report on Monday, June 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. Finally, Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Three analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.